Recurrent Cardiovascular Events Despite Optimal LDL-Cholesterol Reduction: Therapeutic Challenges

被引：0
|
作者：
Elis, Avishay [1 ,2 ]
Giladi, Ela [3 ]
机构：
[1] Rabin Med Ctr, Dept Internal Med C, Beilinson Campus, IL-4941492 Petah Tiqwa, Israel
[2] Meir Med Ctr, Dept Cardiol, Kefar Sava, Israel
[3] Tel Aviv Univ, Fac Med & Hlth Sci, Tel Aviv, Israel
来源：
ISRAEL MEDICAL ASSOCIATION JOURNAL | 2024年 / 26卷 / 12期
关键词：
anticoagulants; glucagon-like peptide-1 receptor agonist (GLP1 RA); lipoprotein(a); low-density lipoprotein choles- terol (LDL-C); triglycerides; GLP-1 RECEPTOR AGONISTS; RISK; LIPOPROTEIN(A); DISEASE; METAANALYSIS; OUTCOMES;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Despite the application of recommended guideline-driven therapies and optimal medical interventions, individuals with established cardiovascular disease remain susceptible to additional cardiovascular incidents, a phenomenon referred to as residual risk. Analyses of clinical trial data reveal significant residual cardiovascular risk in all treated patients, even in the setting of optimal LDL-C reduction, thus enforcing the need to revise the algorithms beyond focusing on LDL-C levels. We present a case that highlights the problem of residual risk upon well controlled LDL-C levels and provide insights for additional measures for residual risk reduction.
引用
收藏
页码：724 / 728
页数：5
相关论文
共 50 条
  • [1] Residual Cardiovascular Risk Despite Optimal LDL Cholesterol Reduction with Statins: The Evidence, Etiology, and Therapeutic Challenges
    Uchechukwu K. Sampson
    Sergio Fazio
    MacRae F. Linton
    Current Atherosclerosis Reports, 2012, 14 : 1 - 10
  • [2] Residual Cardiovascular Risk Despite Optimal LDL Cholesterol Reduction with Statins: The Evidence, Etiology, and Therapeutic Challenges
    Sampson, Uchechukwu K.
    Fazio, Sergio
    Linton, MacRae F.
    CURRENT ATHEROSCLEROSIS REPORTS, 2012, 14 (01) : 1 - 10
  • [3] LDL-cholesterol and cardiovascular events: the lower the better?
    Weitgasser R.
    Ratzinger M.
    Hemetsberger M.
    Siostrzonek P.
    Wiener Medizinische Wochenschrift, 2018, 168 (5-6) : 108 - 120
  • [4] LDL-CHOLESTEROL CORRECTED FOR LP(A)-CHOLESTEROL, RISK THRESHOLDS AND CARDIOVASCULAR EVENTS
    Willeit, P.
    Yeang, C.
    Moriarty, P. M.
    Tschiderer, L.
    Varvel, S. A.
    Mcconnell, J. P.
    Tsimikas, S.
    ATHEROSCLEROSIS, 2020, 315 : E34 - E35
  • [5] LDL-CHOLESTEROL AND CARDIOVASCULAR EVENTS IN PATIENTS WITH DIABETES MELLITUS TYPE 2
    Tudor, C.
    Iana, A.
    Jeberean, R. A.
    Petrus, A.
    Buzas, R.
    ATHEROSCLEROSIS SUPPLEMENTS, 2010, 11 (02) : 33 - 34
  • [6] Coffee, LDL-cholesterol and cardiovascular risk
    La Sala, Lucia
    Pontiroli, Antonio E.
    NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2021, 31 (09) : 2735 - 2736
  • [7] Endothelial dysfunction is frequently present in hyperlipidaemic patients despite adequate reduction of LDL-cholesterol
    Lekakis, J
    Papamichael, C
    Barbaki, P
    Dagre, A
    Stamatelopoulos, K
    Voutsas, A
    Stamatelopoulos, S
    EUROPEAN HEART JOURNAL, 2001, 22 : 651 - 651
  • [8] Beyond statins: New pharmacological targets to decrease LDL-cholesterol and cardiovascular events
    Raschi, Emanuel
    Casula, Manuela
    Cicero, Arrigo F. G.
    Corsini, Alberto
    Borghi, Claudio
    Catapano, Alberico
    PHARMACOLOGY & THERAPEUTICS, 2023, 250
  • [9] Optimal target of LDL cholesterol level for statin treatment: challenges to monotonic relationship with cardiovascular events
    Sakuma, Masashi
    Iimuro, Satoshi
    Shinozaki, Tomohiro
    Kimura, Takeshi
    Nakagawa, Yoshihisa
    Ozaki, Yukio
    Iwata, Hiroshi
    Miyauchi, Katsumi
    Daida, Hiroyuki
    Suwa, Satoru
    Sakuma, Ichiro
    Nishihata, Yosuke
    Saito, Yasushi
    Ogawa, Hisao
    Matsuzaki, Masunori
    Ohashi, Yasuo
    Taguchi, Isao
    Toyoda, Shigeru
    Inoue, Teruo
    Nagai, Ryozo
    BMC MEDICINE, 2022, 20 (01)
  • [10] Optimal target of LDL cholesterol level for statin treatment: challenges to monotonic relationship with cardiovascular events
    Masashi Sakuma
    Satoshi Iimuro
    Tomohiro Shinozaki
    Takeshi Kimura
    Yoshihisa Nakagawa
    Yukio Ozaki
    Hiroshi Iwata
    Katsumi Miyauchi
    Hiroyuki Daida
    Satoru Suwa
    Ichiro Sakuma
    Yosuke Nishihata
    Yasushi Saito
    Hisao Ogawa
    Masunori Matsuzaki
    Yasuo Ohashi
    Isao Taguchi
    Shigeru Toyoda
    Teruo Inoue
    Ryozo Nagai
    BMC Medicine, 20
12345